ArticleJournal of clinical medicine2019

Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes.

Shusuke Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.